The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
US pharma major Eli Lilly and Egyptian firm EVA Pharma have entered into an agreement to expand access to Olumiant (baricitinib) to an estimated 20,000 people in 49 low- to middle-income countries in Africa by 2030. 6 September 2024
Novartis is building two new radioligand therapy (RLT) manufacturing facilities in the USA to enhance its supply chain for cancer treatments. This move supports the growing use of RLTs, a form of precision medicine that targets tumors with radiation. 6 September 2024
Belgium’s largest drugmaker UCB announced a strategic divestment deal in China, underscoring its strategic shift towards innovation and partnership in one of the world’s fastest-growing pharmaceutical markets. 27 August 2024
The UK’s largest pharma company AstraZeneca has rejected claims that it is moving its vaccine operations to the USA, according to media reports. 23 August 2024
Mitsubishi Tanabe Pharma announced the termination of its exclusive sales rights agreements with AnGes for the HGF gene therapy product, Collategene (beperminogene perplasmid) intramuscular injection targeting peripheral arterial diseases in Japan and the USA. 23 August 2024
UK pharma major AstraZeneca has become the only current UK-lis¬ted company to reach a £200 billion ($256.4 billion) valuation, the Financial Times reported today, noting that it is a vindication of the company’s bet on developing a leading portfolio of cancer drugs. 14 August 2024
Japan’s Eisai and US biotech Biogen today revealed that the Ministry of Health and Prevention in the United Arab Emirates (UAE) has approved Leqembi (lecanemab) for the treatment of Alzheimer’s disease (AD). 14 August 2024
US pharma giant Pfizer has announced the publication of real-world results from a cohort of the longitudinal, observational Phase IV THAOS (Transthyretin Amyloidosis Outcomes Survey) study in the Journal of Cardiac Failure. 8 August 2024
Japanese drugmaker Shionogi says that its New Drug Application (NDA) for cefiderocol has been accepted for review by the Center for Drug Evaluation, National Medical Products Administration (NMPA). 5 August 2024
Germany’s Bayer has submitted to the US Food and Drug Administration for approval to market elinzanetant for moderate to severe vasomotor symptoms (VMS), commonly known as hot flashes, associated with menopause. 2 August 2024
PsiOxus, a clinical-stage biotechnology company developing a novel platform technology for the targeted delivery of therapeutic transgenes to solid tumors, has announced the appointment of its new chief executive, Howard Davis. 12 August 2022
The Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Roche's Xofluza (baloxavir marboxil) for the treatment of acute uncomplicated influenza in otherwise healthy children aged five to less than 12 years of age who have been symptomatic for no more than 48 hours. 12 August 2022
USA-based Amneal Pharmaceuticals has announced that it has received Abbreviated New Drug Application (ANDA) approval from the US Food and Drug Administration (FDA) for four generics products. 12 August 2022
The US Food and Drug Administration (FDA) has granted regular approval to Swiss pharma giant Novartis’ Tabrecta (capmatinib) for adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation leading to mesenchymal-epithelial transition (MET) exon 14 skipping. 12 August 2022
Amid the ongoing military conflict between Ukraine and Russia and the ever-tightening sanctions pressure on Russia, the Kremlin is considering investing about 200 billion roubles ($12.1 billion) in the achievement of so-called medicine and pharmaceutical sovereignty. 12 August 2022
French specialty vaccine company Valneva, a late-comer in the race to develop coronavirus vaccines, announced it has suspended manufacturing of VLA2001 and is exploring strategic options. 12 August 2022
Russian drugmaker Biocad is eyeing becoming the largest supplier of oncology drugs for state needs, achieving this by producing analogues of some popular drugs for the treatment of cancer. 11 August 2022
The US Food and Drug Administration is not ready to let French microbiome specialist MaaT Pharma continue work on its acute graft-versus-host disease (aGvHD) candidate. 11 August 2022
Florida, USA-based firm Fortress Biotech has been awarded a $20 million grant to help develop its cytomegalovirus (CMV) vaccine Triplex. 11 August 2022
Belgo-Dutch autoimmune diseases specialist argenx has announced that the European Commission (EC) has approved Vyvgart (efgartigimod alfa-fcab) as an add-on to standard therapy for adults with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive. 11 August 2022
Dutch rare diseases biotech firm ProQR Therapeutics today provided an update on its ophthalmology programs following feedback from the European Medicines Agency (EMA) related to sepofarsen and will now focus exclusively on its Axiomer RNA-editing technology platform. 11 August 2022
Shares of US biopharma company VYNE Therapeutics closed down 22.9% at $0.31 yesterday, having plunged as much as 35%, after it revealed results from the Phase IIa segment of a Phase Ib/IIa clinical trial evaluating FMX114 for the treatment of mild-to-moderate atopic dermatitis (AD) that failed to hit its goal. 11 August 2022
Danish allergy immunotherapy specialist ALK Abello saw its shares rise 8.7% to 153.80 kroner by mid-morning today, as it reported strong financial results for the second quarter of 2022. 11 August 2022
Indian drugmaker Strides Pharma Science today announced that its formulation facility at Singapore underwent a US Food and Drug Administration (FDA) inspection that ended on August 8, 2022. 11 August 2022
Positive top-line results from a Phase III trial of the first CAR T-cell therapy in multiple myeloma have been presented by developers Bristol Myers Squibb and 2seventy bio. 10 August 2022
Gemini Therapeutics and privately-held clinical-stage Disc Medicine today announced a merger agreement to create a NASDAQ-listed, clinical stage biopharma focused on advancing Disc’s pipeline of hematology programs. 10 August 2022
Boston, USA-based engineered regulatory T cells (Tregs) company GentiBio has entered into a collaboration with US pharma major Bristol Myers Squibb to develop new engineered Treg therapies to re-establish immune tolerance and repair tissue in patients living with inflammatory bowel diseases (IBD). 10 August 2022
Efforts on the part of Swiss pharma giant Roche to take on AstraZeneca in the treatment of paroxysmal nocturnal hemoglobinuria (PNH) advanced a step this week. 10 August 2022